Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - State of the art

Supportive Care in Cancer

Volumn 19, Issue SUPPL. 1, 2011, Pages

  Grunberg, Steven M ^g   Warr, David ^a   Gralla, Richard J ^b   Rapoport, Bernardo L ^c   Hesketh, Paul J ^d   Jordan, Karin ^e   Espersen, Birgitte T ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b North Shore LIJ Cancer Institute   (United States)

^c Medical Oncology Centre of Rosebank   (South Africa)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g NONE

Author keywords

Classification; Emetogenicity; Nausea; Vomiting

Indexed keywords

ALEMTUZUMAB; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BENDAMUSTINE; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; IXABEPILONE; METHOTREXATE; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PEMETREXED; STREPTOZOCIN; TOPOTECAN; UNINDEXED DRUG;

ARTICLE; CHEMOTHERAPY INDUCED EMESIS; DRUG CLASSIFICATION; DRUG SAFETY; DRUG SCREENING; HUMAN; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; NAUSEA; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 79953318777     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-1003-x     Document Type: Article

References (15)

1. Ball RS (2006) Issues to consider for preparing ferrets as research subjects in the laboratory. ILAR J 47:348-357
2. Darmani NA, Wang Y, Abad J, Ray AP, Thrush GR, Ramirez J (2008) Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists. Brain Res 1214:58-72
3. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482 (Pubitemid 37466663)
4. Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 104:864-868 (Pubitemid 41113689)
5. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268 (Pubitemid 38580348)
6. Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 13:80-84
7. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DB, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119 (Pubitemid 46606178)
8. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ (1997) Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 89:817-818 (Pubitemid 27242284)
9. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yan HM, Baranowski V (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23:533-543 (Pubitemid 46456901)
10. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469-478
11. Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudio BD, Colman L, Hoelzer K, Jacobs A (2010) Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 18:869-876
12. Ryan JL, Heckler C, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR (2009) Ginger for chemotherapy-related nausea in cancer patients: a URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients. J Clin Oncol 27:15s (suppl; abstr 9511)
13. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative Phase III trial. Lancet Oncol 10:115-124
14. Stockhorst U, Enck P, Klosterhalfen S (2007) Role of classical conditioning in learning gastrointestinal symptoms. World J Gastroenterol 13:3430-3437 (Pubitemid 47162016)
15. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830 (Pubitemid 46179473)